▽veltuzumab - PubMed - NCBI
●01/08 01:06
Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris.Ellebrecht CT, Choi EJ, Allman DM, Tsai DE, Wegener WA, Goldenberg DM, Payne AS. Ellebrecht CT, et al. JAMA Dermatol. 2014 Dec;150(12):1331-5. doi: 10.1001/jamadermatol.2014.1939. JAMA Dermatol. 2014. PMID: 25133328 Free PMC article.Relapse and response to veltuzumab generally correlated wi

▽oral azacitidine - PubMed - NCBI
●01/07 20:04
2025 2Ivanov V, Yeh SP, Mayer J, Saini L, Unal A, Boyiadzis M, Hoffman DM, Kang K, Addo SN, Mendes WL, Fathi AT. Ivanov V, et al. Future Oncol. 2022 Aug;18(26):2879-2889. doi: 10.2217/fon-2022-0450. Epub 2022 Jul 19. Future Oncol. 2022. PMID: 35852098 Free article. Review.

▽Ibritumomab tiuxetan - PubMed - NCBI
●01/07 16:11
Ibritumomab tiuxetan.Riley MB. Riley MB. Clin J Oncol Nurs. 2003 Jan-Feb;7(1):110-2. doi: 10.1188/03.CJON.109-112. Clin J Oncol Nurs. 2003. PMID: 12629947 No abstract available.90Y-ibritumomab tiuxetan in the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.Fink-Bennett DM, Thomas K. Fink-Bennett DM, et al. J Nucl Med Technol. 2003 Jun;31(2):61-8; quiz 69-70. J Nucl Med Technol

▽Japan Adult Leukemia Study Group (JALSG)
●01/07 06:42
2025.01.06ご支援･ご寄付ﾍﾟｰｼﾞを更新しました2025.01.06JALSG参加施設一覧を更新しました

▽CC-486 - PubMed - NCBI
●01/06 16:26
Ivanov V, Yeh SP, Mayer J, Saini L, Unal A, Boyiadzis M, Hoffman DM, Kang K, Addo SN, Mendes WL, Fathi AT. Ivanov V, et al. Future Oncol. 2022 Aug;18(26):2879-2889. doi: 10.2217/fon-2022-0450. Epub 2022 Jul 19. Future Oncol. 2022. PMID: 35852098 Free article. Review.